AbbVie Inc  

(Public, NYSE:ABBV)   Watch this stock  
Find more results for Edward M. Liddy
+0.13 (0.21%)
After Hours: 62.19 -0.03 (-0.05%)
Feb 27, 5:05PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 61.68 - 62.37
52 week 54.24 - 68.12
Open 62.02
Vol / Avg. 5.21M/7.14M
Mkt cap 99.41B
P/E 17.05
Div/yield 0.64/4.11
EPS 3.65
Shares 1.59B
Beta 1.58
Inst. own 69%
Jan 27, 2017
Q4 2016 AbbVie Inc Earnings Release (Estimated)
Jan 11, 2017
AbbVie Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 20.47% 23.22%
Operating margin 34.70% 36.60%
EBITD margin - 42.09%
Return on average assets 8.41% 9.99%
Return on average equity 100.48% 138.75%
Employees 30,000 -
CDP Score - 89 D


1 N Waukegan Rd
NORTH CHICAGO, IL 60064-1802
United States - Map
+1-847-9327900 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women's health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.

Officers and directors

Richard A. Gonzalez Chairman of the Board, Chief Executive Officer
Age: 62
Bio & Compensation  - Reuters
William J. Chase Executive Vice President, Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Michael Severino M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 50
Bio & Compensation  - Reuters
Laura J. Schumacher Executive Vice President, External Affairs, General Counsel and Corporate Secretary
Age: 52
Bio & Compensation  - Reuters
Carlos Alban Executive Vice President - Commercial Operations
Age: 53
Bio & Compensation  - Reuters
Henry O. Gosebruch Executive Vice President, Chief Strategy Officer
Age: 43
Bio & Compensation  - Reuters
Timothy J. Richmond Senior Vice President - Human Resources
Age: 49
Bio & Compensation  - Reuters
Azita Saleki-Gerhardt Ph.D. Senior Vice President - Operations
Age: 52
Bio & Compensation  - Reuters
Thomas A. Hurwich Vice President, Controller
Age: 55
Bio & Compensation  - Reuters
Robert J. Alpern M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters